Valuation: Avacta Group Plc

Market Cap 356M 476M 414M 392M 665M 45.61B 669M 4.67B 1.8B 23.06B 1.78B 1.75B 74.18B P/E 2026 *
-12.2x
P/E 2027 * -14.2x
Enterprise Value 352M 471M 410M 388M 659M 45.16B 662M 4.62B 1.78B 22.84B 1.77B 1.73B 73.44B EV / Sales 2026 *
128x
EV / Sales 2027 * 46.3x
Free-Float
97.08%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Avacta Group Plc

1 day-3.31%
1 week+7.04%
Current month+11.44%
1 month+18.75%
3 months+4.11%
6 months+4.11%
Current year+31.03%
1 week 69
Extreme 69
88
1 month 63
Extreme 63
88
Current year 48
Extreme 48
92
1 year 48
Extreme 48
92
3 years 26
Extreme 26
166.98
5 years 26
Extreme 26
187.98
10 years 13
Extreme 13
291.8
Manager TitleAgeSince
Chief Executive Officer 56 01/04/2024
Director of Finance/CFO 51 22/01/2025
Chief Tech/Sci/R&D Officer - 09/02/2026
Director TitleAgeSince
Director/Board Member 60 03/02/2020
Director/Board Member 71 17/08/2021
Director/Board Member 56 18/03/2022
Date Insider Type Main position Quantity % Market Cap. Importance
9/2/24 A Sell

Chief Financial Officer

500,000 0.1393%
9/2/24 A Free

Chief Executive Officer

3,600,000 1.0027%
9/2/24 A Exercice

Chief Financial Officer

500,000 0.1393%
Change 5-day change 1-year change 3-year change Capi.($)
-3.31%+7.04%+44.76%-33.33% 495M
+1.76%+3.62%+49.92%+101.12% 69.69B
+2.29%+0.32%+37.65%+77.03% 61.24B
+1.14%-3.74%-14.35%+365.92% 26.77B
+0.32%+2.58%+29.26%+14.12% 26.12B
+2.95%+0.54%-0.60%-12.74% 24.07B
+1.49%+5.15%+26.46%-15.89% 20.39B
-0.83%-11.15%+169.70%+295.44% 15.72B
+3.01%+0.27%+49.44%+168.18% 14.07B
+0.17%-4.07%-9.71%+484.05% 14.03B
Average +0.90%+0.00%+38.25%+144.39% 27.26B
Weighted average by Cap. +1.59%+0.22%+36.46%+128.70%

Financials

2026 *2027 *
Net sales 2.75M 3.67M 3.2M 3.03M 5.14M 352M 5.17M 36.06M 13.91M 178M 13.78M 13.49M 573M 8.1M 10.82M 9.42M 8.92M 15.13M 1.04B 15.22M 106M 40.97M 525M 40.6M 39.73M 1.69B
Net income -28.92M -38.63M -33.64M -31.85M -54.03M -3.7B -54.33M -379M -146M -1.87B -145M -142M -6.03B -23.64M -31.58M -27.5M -26.03M -44.16M -3.03B -44.41M -310M -120M -1.53B -118M -116M -4.93B
Net Debt -3.52M -4.7M -4.09M -3.88M -6.57M -451M -6.61M -46.13M -17.8M -228M -17.64M -17.26M -733M 18.98M 25.35M 22.08M 20.9M 35.46M 2.43B 35.66M 249M 95.99M 1.23B 95.13M 93.1M 3.95B
Logo Avacta Group Plc
Avacta Group plc is a United Kingdom-based life sciences company developing peptide drug conjugates (PDC) targeting anti-tumor payloads directly to the tumor. The Company is focused on the development of its proprietary preCISION technology platform. The preCISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preCISION platform harnesses this tumor-specific protease to cleave preCISION peptide drug conjugates and preCISION antibody/Affimer drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity. Its lead program, AVA6000, is a clinical-stage asset which is a preCISION-enabled form of doxorubicin. AVA6103, the Company’s second program, is a preCISION-enabled PDC comprised of the preCISION peptide linked to exatecan, the most potent topoisomerase I (topo I) inhibitor in clinical development.
Employees
81
Date Price Change Volume
17/09/26 GBX 76.00 -3.31% 3,085,033
16/09/26 GBX 78.60 -1.75% 7,733,553
15/09/26 GBX 80.00 +5.96% 4,504,015
14/09/26 GBX 75.50 +3.42% 3,767,784
11/09/26 GBX 73.00 +5.95% 1,612,301
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.7600GBP
Average target price
0.9425GBP
Spread / Average Target
+24.01%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AVCT Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!